Compare Amphastar Pharmaceuticals Inc (AMPH) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs EPAM Systems Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while EPAM Systems Inc trades at $84.52 (market cap $4.38B). The key difference: EPAM Systems Inc is far larger — about 5.3× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | EPAM | |
|---|---|---|
Market Cap | $826.08M | $4.38B |
Sector | Health | Technology |
52-Week High | $30.81 | $221.40 |
52-Week Low | $16.87 | $76.04 |
Enterprise Value | $1.22B | $3.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
EPAM Systems trades at $83.89, down 3.9% in the last session, with a bearish technical signal from moving averages. The company maintains solid profitability with 29% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights EPAM's AI partnerships and upcoming Q2 2026 earnings release. Valuation metrics appear attractive with P/E of 12.05 and P/S of 0.84, well below sector averages.
The stock presents a compelling value opportunity with strong analyst support (65% buy ratings) and a $128.55 consensus price target representing 53% upside potential. Key risks include competitive pressures in IT services and recent net income margin compression from 9.61% in 2024 to 6.96% in 2025. The upcoming Q2 earnings report on July 6, 2026 will be critical for validating growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
